AR030179A1 - Combinaciones de un inhibidor de tirosinquinasa de receptores abl, de pdgf y de kit con un compuesto organico capaz de enlazarse con glicoproteina acido-alfa1, un producto, el uso de dicha combinacion para producir un producto farmaceutico y un producto farmaceutico - Google Patents
Combinaciones de un inhibidor de tirosinquinasa de receptores abl, de pdgf y de kit con un compuesto organico capaz de enlazarse con glicoproteina acido-alfa1, un producto, el uso de dicha combinacion para producir un producto farmaceutico y un producto farmaceuticoInfo
- Publication number
- AR030179A1 AR030179A1 ARP000106887A ARP000106887A AR030179A1 AR 030179 A1 AR030179 A1 AR 030179A1 AR P000106887 A ARP000106887 A AR P000106887A AR P000106887 A ARP000106887 A AR P000106887A AR 030179 A1 AR030179 A1 AR 030179A1
- Authority
- AR
- Argentina
- Prior art keywords
- receptor
- abl
- pdgf
- product
- kit
- Prior art date
Links
- 239000002131 composite material Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 108020003175 receptors Proteins 0.000 abstract 8
- 102000005962 receptors Human genes 0.000 abstract 8
- 108091008606 PDGF receptors Proteins 0.000 abstract 4
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 abstract 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 150000002894 organic compounds Chemical class 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 229940127557 pharmaceutical product Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 abstract 2
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT1999MI002711A ITMI992711A1 (it) | 1999-12-27 | 1999-12-27 | Composti organici |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR030179A1 true AR030179A1 (es) | 2003-08-13 |
Family
ID=11384195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000106887A AR030179A1 (es) | 1999-12-27 | 2000-12-22 | Combinaciones de un inhibidor de tirosinquinasa de receptores abl, de pdgf y de kit con un compuesto organico capaz de enlazarse con glicoproteina acido-alfa1, un producto, el uso de dicha combinacion para producir un producto farmaceutico y un producto farmaceutico |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20030125343A1 (https=) |
| EP (1) | EP1250140B1 (https=) |
| JP (1) | JP2003523325A (https=) |
| CN (1) | CN1304005C (https=) |
| AR (1) | AR030179A1 (https=) |
| AT (1) | ATE432069T1 (https=) |
| AU (1) | AU2171901A (https=) |
| BR (1) | BR0016817A (https=) |
| CA (1) | CA2394944A1 (https=) |
| CO (1) | CO5271710A1 (https=) |
| DE (1) | DE60042283D1 (https=) |
| ES (1) | ES2326307T3 (https=) |
| HK (1) | HK1050993A1 (https=) |
| IT (1) | ITMI992711A1 (https=) |
| PE (1) | PE20010991A1 (https=) |
| PT (1) | PT1250140E (https=) |
| TW (1) | TWI246917B (https=) |
| WO (1) | WO2001047507A2 (https=) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE369894T1 (de) * | 2000-11-22 | 2007-09-15 | Novartis Pharma Gmbh | Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität |
| AU2002315388A1 (en) | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel phenylamino-pyrimidines and uses thereof |
| US7323469B2 (en) | 2001-08-07 | 2008-01-29 | Novartis Ag | 7H-pyrrolo[2,3-d]pyrimidine derivatives |
| GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
| US20050043409A1 (en) * | 2001-10-25 | 2005-02-24 | Chen Ying-Nan Pan | Combinations comprising a selective cyclooxygenase-2 inhibitor |
| GB0201508D0 (en) | 2002-01-23 | 2002-03-13 | Novartis Ag | Organic compounds |
| CA2479257A1 (en) * | 2002-03-21 | 2003-10-02 | Dana-Farber Cancer Institute, Inc. | Inhibition of cell death responses induced by oxidative stress |
| AU2007201830C1 (en) * | 2002-04-23 | 2017-09-07 | Novartis Pharma Ag | High drug load tablet |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| WO2004026930A2 (en) * | 2002-06-26 | 2004-04-01 | The Ohio State University Research Foundation | The method for reducing inflammation using sti-571 or its salt |
| JP2005533838A (ja) * | 2002-07-24 | 2005-11-10 | ノバルティス アクチエンゲゼルシャフト | 未分化甲状腺癌を処置するための４−（４−メチルピペラジン−１−イルメチル）−ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イルアミノ］フェニル］−ベンズアミド |
| DE60313339T2 (de) * | 2002-07-31 | 2008-01-03 | Critical Outcome Technologies, Inc. | Protein tyrosin kinase inhibitoren |
| GB0222514D0 (en) | 2002-09-27 | 2002-11-06 | Novartis Ag | Organic compounds |
| US7629347B2 (en) * | 2002-10-09 | 2009-12-08 | Critical Outcome Technologies, Inc. | Protein tyrosine kinase inhibitors |
| AU2003268185A1 (en) * | 2003-08-25 | 2005-04-11 | Dana-Farber Cancer Institute Inc. | Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias |
| CA2538523A1 (en) * | 2003-09-19 | 2005-03-31 | Novartis Ag | Treatment of gastrointestinal stromal tumors with imatinib and midostaurin |
| TW200517114A (en) * | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
| DK1720853T3 (en) † | 2004-02-11 | 2016-03-29 | Natco Pharma Ltd | HIS UNKNOWN POLYMORPH FORM OF IMATINIBMYLYLATE AND PROCEDURE FOR PREPARING IT |
| MXPA06015237A (es) | 2004-06-29 | 2007-12-10 | Amgen Inc | Pirrolo[2-3-d]pirimidinas que modulan la actividad de ack1 y lck. |
| JP2008508358A (ja) * | 2004-08-02 | 2008-03-21 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | アリール−アミノ置換ピロロピリミジンマルチキナーゼ阻害化合物 |
| ATE519759T1 (de) | 2004-12-30 | 2011-08-15 | Exelixis Inc | Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren |
| US20070059359A1 (en) * | 2005-06-07 | 2007-03-15 | Thomas Backensfeld | Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof |
| US20060275365A1 (en) * | 2005-06-07 | 2006-12-07 | Thomas Backensfeld | Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl) [4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof |
| DE602006015994D1 (de) * | 2005-06-23 | 2010-09-16 | Novartis Ag | Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer |
| EP1979349B1 (en) * | 2005-12-21 | 2010-07-28 | Abbott Laboratories | Anti-viral compounds |
| US7910595B2 (en) * | 2005-12-21 | 2011-03-22 | Abbott Laboratories | Anti-viral compounds |
| WO2007081517A2 (en) | 2005-12-21 | 2007-07-19 | Abbott Laboratories | Anti-viral compounds |
| CA2649755C (en) * | 2006-04-20 | 2014-12-02 | Janssen Pharmaceutica N.V. | Method of inhibiting c-kit kinase |
| EP2043651A2 (en) * | 2006-07-05 | 2009-04-08 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
| US8236950B2 (en) | 2006-12-20 | 2012-08-07 | Abbott Laboratories | Anti-viral compounds |
| EP2121681B1 (en) | 2007-01-11 | 2015-04-15 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
| US20080248548A1 (en) * | 2007-04-09 | 2008-10-09 | Flynn Daniel L | Modulation of protein functionalities |
| EP2081556A1 (en) * | 2007-09-25 | 2009-07-29 | Teva Pharmaceutical Industries Ltd. | Stable imatinib compositions |
| CA2710039C (en) * | 2007-12-26 | 2018-07-03 | Critical Outcome Technologies, Inc. | Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer |
| EP2247596A2 (en) | 2008-01-11 | 2010-11-10 | Natco Pharma Limited | Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents |
| MX353308B (es) | 2008-05-21 | 2018-01-08 | Ariad Pharma Inc | Derivados fosforosos como inhibidores de cinasa. |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| EP2318406B1 (en) | 2008-07-17 | 2016-01-27 | Critical Outcome Technologies, Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| EP2381777A4 (en) | 2008-12-12 | 2012-08-08 | Ariad Pharma Inc | AZAINDOL DERIVATIVES AS KINASEHEMMER |
| ITRM20090578A1 (it) * | 2009-11-10 | 2011-05-11 | Noi Per Voi Onlus | Nuove composizioni per il trattamento di leucemie chemioresistenti e/o di leucemie potenzialmente chemioresistenti. |
| EP2552915B1 (en) | 2010-04-01 | 2017-07-19 | Critical Outcome Technologies Inc. | Compounds for the treatment of hiv |
| US20120115878A1 (en) | 2010-11-10 | 2012-05-10 | John Vincent Calienni | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
| TR201010618A2 (tr) * | 2010-12-20 | 2012-07-23 | Bi̇lgi̇ç Mahmut | İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi |
| PL394169A1 (pl) | 2011-03-09 | 2012-09-10 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania |
| EP2704572B1 (en) | 2011-05-04 | 2015-12-30 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| US20160015708A1 (en) | 2012-02-21 | 2016-01-21 | Ranbaxy Laboratories Limited | Stable dosage forms of imatinib mesylate |
| WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| CN105828822B (zh) | 2013-08-14 | 2019-10-18 | 诺华股份有限公司 | 用于治疗癌症的组合疗法 |
| WO2017078647A1 (en) | 2015-11-05 | 2017-05-11 | Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi | Pharmaceutical compositions of imatinib |
| EP3257499A1 (en) | 2016-06-17 | 2017-12-20 | Vipharm S.A. | Process for preparation of imatinib methanesulfonate capsules |
| US12390468B2 (en) | 2019-01-23 | 2025-08-19 | Novartis Ag | Crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5587459A (en) * | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
| US5750493A (en) * | 1995-08-30 | 1998-05-12 | Raymond F. Schinazi | Method to improve the biological and antiviral activity of protease inhibitors |
| US20030069174A1 (en) * | 1997-03-10 | 2003-04-10 | Ludwig Pichler | Use of human alpha1-acid glycoprotein for producing a pharmaceutical preparation |
| CO4940418A1 (es) * | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| WO2001004125A1 (en) * | 1999-07-13 | 2001-01-18 | Kyowa Hakko Kogyo Co., Ltd. | Staurosporin derivatives |
| DE60037345T2 (de) * | 1999-12-10 | 2008-11-13 | Pfizer Products Inc., Groton | Pyrrolo(2,3-d)pyrimidin-Verbindungen |
-
1999
- 1999-12-27 IT IT1999MI002711A patent/ITMI992711A1/it unknown
-
2000
- 2000-12-08 TW TW089126229A patent/TWI246917B/zh active
- 2000-12-22 ES ES00985244T patent/ES2326307T3/es not_active Expired - Lifetime
- 2000-12-22 DE DE60042283T patent/DE60042283D1/de not_active Expired - Lifetime
- 2000-12-22 CA CA002394944A patent/CA2394944A1/en not_active Abandoned
- 2000-12-22 CN CNB008178976A patent/CN1304005C/zh not_active Expired - Fee Related
- 2000-12-22 HK HK03101801.4A patent/HK1050993A1/zh unknown
- 2000-12-22 WO PCT/EP2000/013161 patent/WO2001047507A2/en not_active Ceased
- 2000-12-22 JP JP2001548102A patent/JP2003523325A/ja active Pending
- 2000-12-22 US US10/169,035 patent/US20030125343A1/en not_active Abandoned
- 2000-12-22 PT PT00985244T patent/PT1250140E/pt unknown
- 2000-12-22 BR BR0016817-3A patent/BR0016817A/pt not_active Application Discontinuation
- 2000-12-22 PE PE2000001393A patent/PE20010991A1/es not_active Application Discontinuation
- 2000-12-22 AT AT00985244T patent/ATE432069T1/de active
- 2000-12-22 AR ARP000106887A patent/AR030179A1/es not_active Application Discontinuation
- 2000-12-22 AU AU21719/01A patent/AU2171901A/en not_active Abandoned
- 2000-12-22 EP EP00985244A patent/EP1250140B1/en not_active Expired - Lifetime
- 2000-12-22 CO CO00097404A patent/CO5271710A1/es not_active Application Discontinuation
-
2009
- 2009-03-04 US US12/397,374 patent/US20090221519A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20090221519A1 (en) | 2009-09-03 |
| BR0016817A (pt) | 2002-10-01 |
| CN1414858A (zh) | 2003-04-30 |
| ITMI992711A0 (it) | 1999-12-27 |
| CO5271710A1 (es) | 2003-04-30 |
| ES2326307T3 (es) | 2009-10-07 |
| EP1250140A2 (en) | 2002-10-23 |
| ITMI992711A1 (it) | 2001-06-27 |
| US20030125343A1 (en) | 2003-07-03 |
| PT1250140E (pt) | 2009-08-24 |
| DE60042283D1 (de) | 2009-07-09 |
| TWI246917B (en) | 2006-01-11 |
| CA2394944A1 (en) | 2001-07-05 |
| HK1050993A1 (zh) | 2003-07-18 |
| WO2001047507A3 (en) | 2002-04-04 |
| ATE432069T1 (de) | 2009-06-15 |
| CN1304005C (zh) | 2007-03-14 |
| EP1250140B1 (en) | 2009-05-27 |
| PE20010991A1 (es) | 2001-10-23 |
| WO2001047507A2 (en) | 2001-07-05 |
| AU2171901A (en) | 2001-07-09 |
| JP2003523325A (ja) | 2003-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR030179A1 (es) | Combinaciones de un inhibidor de tirosinquinasa de receptores abl, de pdgf y de kit con un compuesto organico capaz de enlazarse con glicoproteina acido-alfa1, un producto, el uso de dicha combinacion para producir un producto farmaceutico y un producto farmaceutico | |
| AR048502A1 (es) | Sinergia terapeutica de compuestos anti-cancer | |
| CR8181A (es) | Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer | |
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| BRPI0612845A8 (pt) | composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador | |
| GEP20115283B (en) | Pyrrolopyrimidine compounds and their uses | |
| ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
| CL2009000241A1 (es) | Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer. | |
| UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
| WO2011031474A3 (en) | Use of metformin in cancer treatment and prevention | |
| BRPI0606996A2 (pt) | combinação de compostos orgánicos, uso da mesma e composição farmacêutica | |
| AR074778A1 (es) | Composicion farmaceutica, con anticuerpo monoclonal humano anti - igf-ir. | |
| AR047988A1 (es) | Combinaciones antineoplásicas de cci-779 y rituximab | |
| NO20060871L (no) | Azepinderivater som farmasoytiske midler | |
| AR044039A1 (es) | Combinaciones antineoplasicas | |
| WO2003063787A3 (en) | Non-steroidal analogs of 2-methoxyestradiol | |
| CU20090007A6 (es) | Un compuesto farmacéutico y un proceso del mismo | |
| CR20190429A (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA-DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
| PL342614A1 (en) | Anticarcinogenic drugs | |
| WO2022061155A9 (en) | Imidazopyridazine and imidazopyrazine compounds as inhibitors of cdk7 | |
| Guilhot et al. | Significant Higher Rates of Undetectable Molecular Residual Disease and Molecular Responses with Pegylated Form of Interferon a2a in Combination with Imatinib (IM) for the Treatment of Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukaemia (CML) Patients (pts): Confirmatory Results at 18 Months of Part 1 of the Spirit Phase III Randomized Trial of the French CML Group (FI LMC). | |
| BRPI0507482A (pt) | combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap | |
| BR0112122A (pt) | Composto de rutênio (ii) , uso de um composto, composição farmacêutica, método para tratar e/ou prevenir o câncer, e, processo para preparar um composto | |
| AR049135A1 (es) | Composicion,metodo, kit y tratamiento con oxaliplatino y un inhibidor del egfr,como erlotinib | |
| BRPI0514187A (pt) | composto, e, droga preventiva ou uma droga terapêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |